Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. (NMRA): 11 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.6 months
D/E 1.18
Lead: Phase 3
11 candidates
1 upcoming, next in ~348d
0 buys · 4 sells (180d)
A transparent, data-derived signal for Neumora Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$329.8M
Cash
$147.1M
Quarterly Burn
$46.4M
Runway
9.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| m4 pam | Preclinical |
| navacaprant | Phase 3 |
| nmra-215 | Phase 1 |
| nmra-266 | Phase 1 |
| nmra-323511 | Phase 1 |
| nmra-335140 | Phase 2 |
| nmra-511 | Phase 3 |
| nmra-898 | Phase 1 |
| nmra-ck1δ | Preclinical |
| nmra-gcase | Preclinical |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Frequently asked questions
How many drug candidates are in Neumora Therapeutics, Inc.'s pipeline?
Neumora Therapeutics, Inc. (NMRA) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Neumora Therapeutics, Inc.'s lead drug candidate?
Neumora Therapeutics, Inc.'s most advanced tracked candidate is m4 pam (Preclinical) for Schizophrenia.
What is Neumora Therapeutics, Inc.'s next catalyst?
Neumora Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep" — expected June 1, 2027.
What is Neumora Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Neumora Therapeutics, Inc. has approximately 9.6 months of cash runway.
What is Neumora Therapeutics, Inc.'s market capitalization?
Neumora Therapeutics, Inc.'s market capitalization is approximately $329.8M.
Get the full picture on Neumora Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.